Methotrexate saves lives: a pearl of observational research.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. Rheumatoid arthritis-related interstitial lung disease (RA-ILD): a possible association between disease activity and prognosis.Clinical rheumatology · 2022
   Article
2. Rheumatoid arthritis-related interstitial lung disease (RA-ILD): methotrexate and the severity of lung disease are associated to prognosis.Clinical rheumatology · 2017
   Article
3. MMP-3 as a predictor for structural remission in RA patients treated with MTX monotherapy.Arthritis research & therapy · 2016
   Article

Corrections and comments

• Comment on
  Propensity-adjusted association of methotrexate with overall survival in rheumatoid arthritis.2013

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as